EUVIMEDEUVIMED entdecken
Crossref

A Hip New Standard

Naomi M Turner iD, Marissa Song Mayeda iD, Bryanna De Lima iD, Darin Friess, Yee-Cheen Doung iD, Kathleen Drago iD

Journal of Bone and Joint Surgery · 2025

DOI: 10.2106/jbjs.24.00766 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Bone and Joint Surgery, 2025. Verfasst von Naomi M Turner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health and Science University, Portland, Oregon. Hauptthemen laut MEDLINE: Zoledronic Acid, Bone Density Conservation Agents, Hip Fractures, Osteoporosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Osteoporosis continues to be underdiagnosed and inadequately treated in older hip-fracture patients. Our aim was to improve the rate of osteoporosis treatment with IV bisphosphonate therapy in eligible patients admitted for hip-fracture surgery.

Methods

The present study was designed as a quality improvement initiative using Plan-Do-Study-Act (PDSA) cycles at an academic medical center in Portland, Oregon, over 2.5 years. A protocol was developed (1) to administer IV zoledronate on postoperative day 2 to inpatients aged ≥50 years who underwent surgery for a low-energy hip fracture and (2) to formally diagnose osteoporosis during admission. The protocol was introduced across 3 care settings in a stepped-wedge manner. Outcome measures were the percentage of inpatient zoledronate administered to eligible patients and formal documented diagnosis of osteoporosis. Balance measures included fever after administration and hospital length of stay (LOS). Measures were assessed through quarterly chart review and tracked via control charts.

Results

The rate of zoledronate administration significantly increased from 34.5% (29 of 84) to 74.6% (53 of 71) following the second PDSA cycle (p < 0.001). Documented osteoporosis diagnosis also significantly improved from 51.0% (53 of 104) to 85.7% (96 of 112) following the second PDSA cycle (p < 0.001). No significant differences were shown for hospital LOS, and 1 of 82 patients had medical work-up for post-infusion acute phase reaction after administration.

Conclusions

This initiative was effective at improving osteoporosis diagnosis and treatment among older hip-fracture patients at our institution. Protocol development for administrating inpatient zoledronate after hip fracture is a reliable way to predictably offer bone health care and secondary-fracture prevention to hip-fracture patients and can be adapted and implemented at other institutions. Level of Evidence: Diagnostic Level III . See Instructions for Authors for a complete description of levels of evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zoledronic AcidBone Density Conservation AgentsHip FracturesOsteoporosisQuality ImprovementDiphosphonatesImidazolesOsteoporotic FracturesHumansFemaleAgedMaleMiddle AgedAged, 80 and overAdministration, IntravenousLength of Stay

Substanzen

Zoledronic AcidBone Density Conservation AgentsDiphosphonatesImidazoles

Autor:innen und Institutionen

  • Oregon Health and Science University, Portland, Oregon.

ORCID-Profile: Naomi M Turner, Marissa Song Mayeda, Bryanna De Lima, Yee-Cheen Doung, Kathleen Drago

Zitieren

APA

Turner, N. M., Mayeda, M. S., De Lima, B., Friess, D., Doung, Y. C., & Drago, K. (2025). A Hip New Standard. Journal of Bone and Joint Surgery. https://doi.org/10.2106/jbjs.24.00766

Vancouver

Turner NM, Mayeda MS, De Lima B, Friess D, Doung YC, Drago K. A Hip New Standard. Journal of Bone and Joint Surgery. 2025. doi:10.2106/jbjs.24.00766

BibTeX
@article{Turner2025,
  author = {Turner, Naomi M and Mayeda, Marissa Song and De Lima, Bryanna and Friess, Darin and Doung, Yee-Cheen and Drago, Kathleen},
  title = {A Hip New Standard},
  journal = {Journal of Bone and Joint Surgery},
  year = {2025},
  doi = {10.2106/jbjs.24.00766}
}
Kostenlos starten →